They share the same source but are fundamentally different compounds. Here's the mechanism-level comparison — fat loss, side effects, safety profile, and when each one makes sense.
Research context only. Neither compound is FDA-approved for general fat loss. This comparison is for educational purposes based on published data.
AOD-9604 and full HGH are often conflated because one comes from the other. But using them interchangeably is a mistake — they have fundamentally different activity profiles, different risk profiles, and different use cases.
| AOD-9604 | Full HGH | |
|---|---|---|
| Type | HGH fragment (176-191) | Full 191 AA recombinant HGH |
| IGF-1 elevation | None | Significant |
| Anabolic activity | None | Significant |
| Blood glucose effect | None | Raises (insulin resistance) |
| Fat loss mechanism | Direct lipolysis / beta-3 | IGF-1 mediated + direct |
| Regulatory status | GRAS (food); Phase 2 trials | FDA approved (Rx only — deficiency) |
| Research peptide cost | Low–moderate | High |
| Side effect profile | Minimal in trials | Significant at higher doses |
Human growth hormone is a 191 amino acid protein. It does two distinct jobs via two distinct mechanisms:
The first ~175 amino acids of HGH bind the GH receptor, triggering IGF-1 production in the liver. IGF-1 drives protein synthesis, bone growth, and cell proliferation. This is the "growth" in growth hormone.
The last 16 amino acids — AOD-9604 — activate fat cell lipolysis and inhibit lipogenesis through beta-3 adrenergic pathways. This is the "fat burning" in growth hormone, and it happens independently of IGF-1.
When you inject full HGH, you get both effects simultaneously. When you inject AOD-9604, you get only the fat metabolism effect. The growth-promoting machinery stays silent.
Why this isolation matters: Full HGH's growth-promoting activity is what causes the problematic side effects — insulin resistance, fluid retention, joint pain, potential tumor promotion. AOD-9604 skips that entire pathway. You get targeted lipolysis without the baggage.
Full HGH does produce fat loss — it's well-documented. But it does so through a mix of direct lipolysis and indirect IGF-1-mediated metabolic effects. The total fat loss from supraphysiological HGH doses can be substantial, but it comes with corresponding side effects.
AOD-9604's Phase 2 data showed meaningful fat mass reduction — but the magnitude is more modest than supraphysiological HGH. The tradeoff: AOD-9604's side effect profile is dramatically cleaner.
| Outcome | AOD-9604 | Full HGH (supraphysiological) |
|---|---|---|
| Fat mass reduction | Moderate (Phase 2 data) | Significant (dose-dependent) |
| Visceral fat targeting | General lipolysis | Some visceral preference |
| Lean mass effect | Preserved (neutral) | Anabolic — increases lean mass |
| Metabolic markers | Unchanged / favorable | Worsened (glucose/insulin) |
| Side effect burden | Low in trials | High at effective doses |
| Post-cycle suppression | None expected | Suppresses endogenous GH production |
HGH's hidden cost: Supraphysiological HGH suppresses your body's own GH production via somatostatin feedback. Long-term exogenous HGH use can leave the GH axis blunted after cycling off. AOD-9604 doesn't interact with the GH axis in this way — no suppression expected.
This is where the comparison becomes most stark. HGH's side effects are the direct result of its IGF-1-mediated activity — and they're dose-dependent and well-documented from decades of clinical use and abuse.
| Side Effect | AOD-9604 | Full HGH |
|---|---|---|
| Fluid retention / edema | Not observed in trials | Common at higher doses |
| Joint pain (arthralgia) | Not reported | Common |
| Carpal tunnel | Not reported | Known risk |
| Insulin resistance | Not observed | Dose-dependent risk |
| Tumor promotion risk | No IGF-1 elevation — low concern | IGF-1 elevation — monitored risk |
| Endogenous GH suppression | Not expected | Occurs with prolonged use |
| Injection site reactions | Mild, occasional | Mild, occasional |
The honest take: These are not equivalent compounds with the same risk-benefit tradeoff. AOD-9604 is a precision tool for fat metabolism research. Full HGH is a broad-spectrum compound that builds muscle, burns fat, and causes significant systemic effects. Choose based on your research objectives and risk tolerance.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator